ChemoCentryx Stock Price

0.24 (1.88%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
ChemoCentryx Inc CCXI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.24 1.88% 13.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.79 12.79 13.46 13.06 12.76
Bid Price Ask Price Spread News
12.85 13.00 0.15 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,413 2,817,314 $ 13.10 $ 36,910,324 3,399,436 9.53 - 70.29
Last Trade Time Type Quantity Stock Price Currency
19:59:52 formt 100 $ 13.00 USD

ChemoCentryx Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 906.74M 69.75M 47.12M $ 64.39M $ -56.93M -0.85 -14.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 331.69k 4.50%

more financials information »

ChemoCentryx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CCXI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.1214.2312.1613.264,481,913-0.12-0.91%
1 Month9.7614.239.749312.233,625,8703.2433.2%
3 Months51.2553.589.5315.383,612,665-38.25-74.63%
6 Months62.9970.299.5321.431,922,448-49.99-79.36%
1 Year57.6470.299.5329.261,241,110-44.64-77.45%
3 Years12.3070.296.1628.23767,9320.705.69%
5 Years4.3170.293.9525.48538,2308.69201.62%

ChemoCentryx Description

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.